EphB4 Antibody (4A12G8): sc-130062
- EphB4 Antibody (4A12G8) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against a recombinant protein corresponding to amino acids 771-987 of EphB4 of human origin
- recommended for detection of EphB4 of mouse, rat and human origin by WB, IF, IHC(P) and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for EphB4 Antibody (4A12G8) for WB and IHC(P) applications. These reagents are now offered in bundles with EphB4 Antibody (4A12G8) (see ordering information below).
EphB4 Antibody (4A12G8) is a mouse monoclonal IgG1 antibody that detects EphB4 in mouse, rat, and human samples through applications such as western blotting (WB), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). EphB4 is a member of the Eph receptor family, which is the largest group of receptor protein tyrosine kinases identified to date, and plays a crucial role in various biological processes, including cell signaling, tissue development, and the formation of the nervous system. EphB4 protein is primarily located on the cell surface, where EphB4 interacts with ephrin-B2 ligands to mediate bidirectional signaling that influences cell positioning and movement during embryonic development. This spatial regulation is vital for processes such as angiogenesis and neural patterning, making EphB4 a significant target for research in developmental biology and potential therapeutic interventions in diseases like cancer. Anti-EphB4 antibody (4A12G8) provides a reliable tool for studying the expression and function of this important receptor in various biological contexts.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EphB4 Antibody (4A12G8) References:
- Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. | Amyere, M., et al. 2017. Circulation. 136: 1037-1048. PMID: 28687708
- Targeting receptor tyrosine kinase EphB4 in cancer therapy. | Chen, Y., et al. 2019. Semin Cancer Biol. 56: 37-46. PMID: 28993206
- EphrinB2-EphB4-RASA1 Signaling in Human Cerebrovascular Development and Disease. | Zeng, X., et al. 2019. Trends Mol Med. 25: 265-286. PMID: 30819650
- The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis. | Du, E., et al. 2020. Mol Biol Rep. 47: 4681-4690. PMID: 32488576
- EphrinB2-EphB4 Signaling in Neurooncological Disease. | Piffko, A., et al. 2022. Int J Mol Sci. 23: PMID: 35163601
- EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. | Bhatia, S., et al. 2022. Nat Commun. 13: 3535. PMID: 35725568
- Insulin induces insulin receptor degradation in the liver through EphB4. | Liu, X., et al. 2022. Nat Metab. 4: 1202-1213. PMID: 36131205
- Divergent Roles of Ephrin-B2/EphB4 Guidance System in Pulmonary Hypertension. | Crnkovic, S., et al. 2023. Hypertension. 80: e17-e28. PMID: 36519465
- EPHB4-RASA1-Mediated Negative Regulation of Ras-MAPK Signaling in the Vasculature: Implications for the Treatment of EPHB4- and RASA1-Related Vascular Anomalies in Humans. | Chen, D., et al. 2023. Pharmaceuticals (Basel). 16: PMID: 37259315
- EPHB4-RASA1 Inhibition of PIEZO1 Ras Activation Drives Lymphatic Valvulogenesis. | Chen, D., et al. 2024. Circ Res. 135: 1048-1066. PMID: 39421925
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EphB4 Antibody (4A12G8) | sc-130062 | 200 µg/ml | $322.00 | |||
EphB4 Antibody (4A12G8): m-IgG Fc BP-HRP Bundle | sc-539801 | 200 µg Ab; 10 µg BP | $361.00 | |||
EphB4 Antibody (4A12G8): m-IgG1 BP-HRP Bundle | sc-541719 | 200 µg Ab; 20 µg BP | $361.00 |